A trial to learn how much budesonide, glycopyrronium, and formoterol fumarate (BGF) gets into and moves throughout the body when it is taken with hydrofluoroolefin (HFO) compared to when it is taken with hydrofluoroalkane (HFA) in healthy adults
Phase 1
- Conditions
- ot applicable, healthy volunteersTherapeutic area: Not possible to specify
- Registration Number
- CTIS2023-504089-43-00
- Lead Sponsor
- AstraZeneca AB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the pharmacokinetic/pharmacodynamic profiles of BGF in HFO vs HFA propellants in healthy adults?
How does HFO-based delivery of budesonide, glycopyrronium, and formoterol compare to HFA in systemic corticosteroid absorption?
Which biomarkers correlate with drug distribution of BGF combinations via HFO or HFA in Phase I trials?
What adverse events are associated with HFO vs HFA formulations of BGF in AstraZeneca's Phase I study?
Are there alternative inhaled combination therapies using HFO propellants for respiratory disease management?